In the case of radical treatment initially, number of cycles of second-line chemotherapy, hypertension and BRAF mutation, a patient with 40 cycles of first-line chemotherapy, without radical treatment initially, with 35 cycles of second-line chemotherapy, no mutation in BRAF gene, and without hypertension is assigned 50, 35, 0, 25 and 0 points, respectively, which gives 110 points in total which corresponds to 0.68 and 0.4 of one- and two-year survival probability after Trifluridine/Tipiracil initiation. Here, BRAF is linked to hypertensive disorder.